Multiple Sclerosis Clinical Trial
— EMOSOCIAL-MSOfficial title:
Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis
Verified date | February 2019 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In addition to the physical, cognitive and psychological symptoms experienced by individuals
with Multiple Sclerosis (MS), there is new research which indicates that some individuals
with MS have a deficit in emotional processing, specifically, facial affect recognition.
Emotional processing is defined as "a central aspect of social cognition". Models of social
cognition indicate that emotional processing is an essential component of interpersonal
relationships. The failure to accurately perceive other's emotions has been shown to lead to
difficulty in social relationships, misinterpreting other's affect, and consequently,
inappropriate responding.
However, even though a significant number of individuals with MS have impairments in
emotional processing, we do not yet have an understanding of how these impairments affect the
social functioning of individuals with MS, including the impact of these deficits on family
structure. It is well-known that MS impacts one's social functioning including factors such
as employment, daily living activities and interpersonal relationships. Recently a strong
correlation was observed between reduced social participation in MS and quality of life.
There is evidence to suggest that emotional processing deficits lie at the heart of this
reduced social participation in persons with MS, leading to decreased social functioning and
thus reduced quality of life. However, to date, this hypothesis has not been tested.
Status | Completed |
Enrollment | 91 |
Est. completion date | January 28, 2019 |
Est. primary completion date | January 28, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria (patient group): - Age 18-45 years; - MS diagnosis according to McDonald criteria (Polman et al., 2005); - RRMS; - Disease duration < 15 years; - Fluent French speaker; - Have a significant other (family members or close friends) who was willing to complete the informant questionnaire BAFQ; - Being affiliated to health insurance; - Having signed an informed consent (later than the day of inclusion and before any examination required by research). Inclusion Criteria (healthy control): - Age 18-45 years - Fluent French speaker; - Have a significant other (family members or close friends) who was willing to complete the informant questionnaire BAFQ. - Being affiliated to health insurance - Having signed an informed consent (later than the day of inclusion and before any examination required by research) Exclusion Criteria (patient group): - Other progressive neurological disease; - psychiatric comorbidity including severe depression according to Diagnostic and Statistical Manual-IV (DSM-IV); - alcohol or other addiction to toxic; - EDSS> 6; - Disabling visual or motor problems preventing participation to neuropsychological assessments; - relapse since less than one month; - change of disease-modifying therapy or psychotropic drug since less than three month; - change of psychotropic drug since less than one month; - Prior neuropsychological testing with the same tests less than one year prevents the participant to participate at this study. - Illiteracy, is unable to count or to read; - Being under guardianship. - Pregnant or breastfeeding women; Exclusion Criteria (healthy control): - History of neurological disease; - family history of MS; - psychiatric comorbidity including severe depression according to DSMIV; - alcohol or other toxic addiction; - usage of psychotropic drugs; - Known cognitive complaint or neuropsychological affection; - Prior neuropsychological testing with the same tests less than one year prevents the participant to participate at this study. - Illiteracy, is unable to count or to read; - Being under guardianship. - Pregnant or breastfeeding women; |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux | Bordeaux | |
France | CHU de Dijon | Dijon |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux | FONDATION POUR L'AIDE A LA RECHERCHE SUR LA SCLEROSE EN PLAQUES |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Interaction between measures of emotional processing (z score) and functional measures of social interaction | among the 3 groups (impaired MS, no impaired MS and HS) | At inclusion (day 0) | |
Secondary | Correlation between measures of emotional processing with cognitive testing (z scores by domain) and cognitive functioning evaluated by significant other | (BAFQ) | At inclusion (day 0) | |
Secondary | Correlation between measures of emotional processing and quality of life measures | (MUSIQoL questionnaire). | At inclusion (day 0) | |
Secondary | Impact of the cognitive impairment on the relationship of emotional processing (z score) with interpersonal relationships (family, friendship, marital) and society integration and social functioning. | At inclusion (day 0) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |